A stock forecast, quote, news & analysis

Key Takeaways

• Agilent Technologies shares rose roughly 9.6% over the trailing 30 days, trading near $173.
• Fiscal third-quarter results beat expectations, with revenue up 7.3% on a core basis and adjusted EPS up 14% year over year, excluding tariff refunds.
• Management raised full-year fiscal 2026 guidance, citing improving end markets, renewed China momentum, and strong pharma and instrument demand.
• Growth is being driven by liquid chromatography (LC) and gas chromatography (GC) replacement cycles, GLP-1-related pharma demand, and the Ignite operating system.
• The Advanced Therapeutics CDMO business grew nearly 30% in the quarter, while instrument book-to-bill remained above 1.0 for a 10th consecutive quarter.

Current Market Snapshot

Agilent Technologies shares have extended a multi-month advance, gaining about 9.6% over the trailing 30 days to trade near $173. The move followed a stronger-than-expected fiscal third-quarter report and an upward revision to full-year guidance. Momentum reflects improving demand across pharmaceutical, chemicals and advanced materials, and diagnostics end markets, supported by an ongoing instrument replacement cycle and steady market-share gains. Broader life-sciences and lab-tools sentiment has also firmed as customer capital budgets stabilize and demand in China recovers.

Agilent Technologies (A) Business Overview and Competitive Position

Agilent Technologies is a global provider of analytical and clinical laboratory technologies, delivering instruments, software, consumables, and services across the life sciences, diagnostics, and applied chemical markets. Its portfolio includes liquid chromatography (LC), gas chromatography (GC), and mass spectrometry systems, complemented by a substantial recurring-revenue base of consumables, services, and software through its CrossLab group. The company reports results across three segments: the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. Agilent generated approximately $6.95 billion in revenue in fiscal 2025 and employs roughly 18,000 people worldwide. Key competitive strengths include a large installed base, a high-margin recurring revenue stream, and a diversified geographic footprint that has helped the company win share across workflows and regions.

Recent Developments Driving A

Agilent's third-quarter fiscal 2026 results, reported in late August, were the primary catalyst behind the recent share advance. Revenue reached $1.88 billion, up 8.1% on a reported basis and 7.3% on a core basis, while adjusted earnings per share came in at $1.62, or $1.56 excluding a tariff-refund benefit, up 14% year over year. Both figures exceeded consensus estimates.

Pharma revenue grew 12% in the quarter, with GLP-1-related demand rising more than 70% year over year. The Advanced Therapeutics contract development and manufacturing (CDMO) business grew nearly 30%, and China revenue increased 9%, well ahead of expectations. Instrument demand remained healthy, with book-to-bill above 1.0 for a 10th straight quarter and strong early traction for new products such as the 9500 Triple Quad ICP-MS and flagship GC systems.

Management raised its full-year fiscal 2026 outlook to revenue of $7.49 billion to $7.51 billion and adjusted EPS of $6.18 to $6.21, or $6.12 to $6.15 excluding tariff refunds. The company also highlighted margin expansion from its Ignite transformation program, with operating margin up 210 basis points year over year excluding refunds. Other recent developments include the closing of the Biocare acquisition in late June, new CE-IVD-labeled TapeStationDx products for clinical next-generation sequencing quality control, and refreshed board leadership.

Trending AI Robots

For traders and investors looking to complement their own research with systematic signals, Tickeron's Trending AI Robots page curates a focused selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that collectively monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving users a way to compare different automated approaches across market conditions. The page is designed to surface currently relevant strategies rather than an exhaustive list, helping users identify AI tools that align with their own objectives and risk tolerance.

2026 Outlook and What Investors Should Watch

Looking ahead, the key drivers for Agilent include the pace of the LC and GC replacement cycles, sustained pharma and GLP-1-related demand, and the trajectory of the China recovery. Investors will also monitor the ramp of the Advanced Therapeutics CDMO capacity expansions, where new production trains are expected to begin contributing over the next several quarters, as well as continued execution of the Ignite efficiency program. Macroeconomic factors such as tariffs, currency movements, and geopolitical uncertainty remain relevant, as do semiconductor and advanced-materials spending trends. The company's fourth-quarter guidance implies continued mid-single-digit core growth, and upcoming earnings releases will provide further clarity on whether current momentum carries into fiscal 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations